Sunobinop
 | |
| Clinical data | |
|---|---|
| Other names | IMB-115 |
| Drug class | Nociceptin receptor agonist |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C26H33N3O3 |
| Molar mass | 435.568 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Sunobinop (developmental code names V117957; IMB-115) is a high affinity small molecule nociceptin receptor partial agonist.[1]
As of Feb 2024, it is under clinical investigation for the treatment of insomnia/alcohol use disorder, interstitial cystitis, and overactive bladder syndrome.[2][3] It was previously also under investigation for the treatment of fibromyalgia.[1]
Pharmacology[edit]
Sunobinop has nanomolar affinity (Ki) and efficacy (EC50) at human recombinant nociceptin/orphanin-FQ peptide (NOP) receptors. It has a high degree of functional selectivity for the NOP receptor. Sunobinop is a low affinity antagonist at human mu and kappa opioid receptors, and is a low affinity weak partial agonist at human delta opioid receptors.[4]
Clinical trials[edit]
Sunobinop was generally well tolerated in 3 studies involving 70 healthy subjects at doses that ranged from 0.6 to 30 mg. The most prominent adverse event was dose-dependent sedation/somnolence, which was more common at doses greater than 10 mg. In these studies, most of the absorbed sunobinop was excreted unchanged via rapid renal elimination.[5]
The safety and effectiveness of sunobinop has not been evaluated by the FDA. There is no guarantee that sunobinop will successfully complete development or gain FDA approval.[2]
See also[edit]
References[edit]
- ^ a b "Sunobinop - Shionogi/Imbrium Therapeutics". AdisInsight. Springer Nature Switzerland AG.
- ^ a b "Pipeline". Imbrium Therapeutics. Retrieved May 1, 2024.
- ^ WO application 2018020418, Harris SC, Kapil RP, Kyle DJ, Whiteside G, "Treatment and prevention of sleep disorders", published 2018-02-01, assigned to Purdue Pharma L.P.
- ^ Whiteside GT, Kyle DJ, Kapil RP, Cipriano A, He E, Zhou M, et al. (January 2024). "The nociceptin/orphanin FQ receptor partial agonist sunobinop promotes non-REM sleep in rodents and patients with insomnia". The Journal of Clinical Investigation. 134 (1). doi:10.1172/JCI171172. PMC 10760950. PMID 37883189.
- ^ Cipriano A, Kapil RP, Zhou M, Shet MS, Whiteside GT, Willsie SK, et al. (March 13, 2024). "Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-Ascending Doses of Sunobinop in Healthy Participants". Clinical Pharmacology in Drug Development. doi:10.1002/cpdd.1394. Retrieved May 1, 2024.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |